À propos de cet article

Citez

1. Badurski E. (2005). Choroby metaboliczne kości. Borgis. Warszawa.Search in Google Scholar

2. Boyce B.R., Xing L.: Biology of RANK, RANKL and osteoprotegerin. Arthritis Research & Therapy, 9, 1, 2007. online: http://arthritis-research.com/content/9/S1/S1.10.1186/ar2165192451617634140Search in Google Scholar

3. Crotti T. et al.: Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J. Periodontal Res., 38, 380-387, 2003.10.1034/j.1600-0765.2003.00615.x12828654Search in Google Scholar

4. Darmochwał-Kolarz D. et al.: The concentrations of markers of bone turnover in normal pregnancy and preeclampsia. Hypertens. Pregn., 31, 166-176, 2012.10.3109/10641955.2010.48408420822429Search in Google Scholar

5. Heath D.J. et al.: An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res., 67, 202-208, 2007.10.1158/0008-5472.CAN-06-128717210700Search in Google Scholar

6. Holen I., Shipman C.M.: Role of osteoprotegerin (OPG) in cancer. Clin. Sci., 110, 279-291, 2006.10.1042/CS2005017516464170Search in Google Scholar

7. Jankowska A. (2009). Stężenie osteoprotegeryny i liganda receptora aktywującego czynnik jądrowy kappa b w przebiegu nieswoistych zapaleń jelit u dzieci. Praca na stopień doktora nauk medycznych. Gdańsk.Search in Google Scholar

8. Kiryłów E., Kamieński G.: Miejsce biochemicznych markerów obrotu kostnego w zaleceniach diagnostyczno-leczniczych osteoporozy. Pol. Merk. Lek., 25, 48, 2008.Search in Google Scholar

9. Kostenuik P.J.: Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Current Opin Pharmacol., 5, 618-625, 2005.10.1016/j.coph.2005.06.00516188502Search in Google Scholar

10. Kryśkiewicz E., Lorenc R.S.: Szlak RANKL/RANK/OPG i jego znaczenie w fizjologii i patofizjologii kości. Terapia (online), 3, 177, 2006.Search in Google Scholar

11. Lerner U.H.: New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit. Rev. Oral Biol. Med., 15, 64-81, 2004.10.1177/15441113040150020215059943Search in Google Scholar

12. Liu D. et al.: Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int. J. Mol. Med., 11, 17-21, 2003.10.3892/ijmm.11.1.1712469211Search in Google Scholar

13. Manolagas S.C.: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 21, 115-137, 2000.10.1210/edrv.21.2.039510782361Search in Google Scholar

14. Mogi M. et al.: Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J. Dent. Res., 83,166-169, 2004.10.1177/15440591040830021614742657Search in Google Scholar

15. Nagasawa T. et al.: Roles of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontol. 2000, 43, 65-84, 2007.10.1111/j.1600-0757.2006.00185.x17214836Search in Google Scholar

16. Nagasawa T.A et al.: LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin. Exp. Immunol., 130, 338-344, 2002.10.1046/j.1365-2249.2002.01990.x190652312390325Search in Google Scholar

17. Rahnama M., Świątkowski W., Zaręba S.: An assessment of the alkaline and acid phosphatase activity in rats serum during experimental postmenopausal osteoporosis. Rocz. Państ. Zakł. Hig., 53, 3, 283-291, 2002.Search in Google Scholar

18. Rahnama M.: New aspects of osteoporosis - a literature review. Ann. UMCS Sect. D., 57, 2, 365-368, 2002.Search in Google Scholar

19. Rahnama M. (2009): Osteoporoza pomenopauzalna w badaniach doświadczalnych i klinicznych. Ocena wpływu poziomu wybranych markerów obrotu kostnego, ekspresji ich genów oraz szlaku RANKL/RANK/OPG na gęstość tkanki kostnej. Medical University of Lublin.Search in Google Scholar

20. Rogers A., Estell R.: Circulating osteoprotegerin and receptor activator for nuclear factor B ligand: clinical utility in metabolic bone disease assessment. J. Clin. Endocrinol. Metab. 90, 6323-6331, 2005.10.1210/jc.2005-079416105967Search in Google Scholar

21. Roodman G.D.: Regulation of osteoclast differentiation. Ann. N.Y. Acad. Sci., 1068, 100-109, 2006.10.1196/annals.1346.01316831910Search in Google Scholar

22. Schoppet M., Preissner K.T., Hofbauer L.C.: RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol., 22, 549-533, 2002.10.1161/01.ATV.0000012303.37971.DA11950689Search in Google Scholar

23. Stanisławowski M., Kmieć Z.: Udział RANK, RANKL i OPG w osteolizie towarzyszącej nowotworom. Post. Hig. Med. Dosw. (online)., 63, 234-241, 2009.Search in Google Scholar

24. Torring O. (2005). Metabolizm tkanki kostnej. W: Hiperkalcemia w przebiegu nowotworów złośliwych i innych stanach chorobowych. Accurant Information AB. Uppsala, Elanders Tofters.Search in Google Scholar

25. Vernal R. et al.: High expression levels of receptor activator of nuclear factor-kappa B ligand associated with human chronic periodontitis are mainly secreted by CD4+ T lymphocytes. J. Periodontol., 77, 10, 1772-1780, 200610.1902/jop.2006.05037617032122Search in Google Scholar

26. Vitoratos N. et al.: Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. Eur. J. Obstet. Gynecol. Reprod. Biol., 154, 2, 141-145, 2011.10.1016/j.ejogrb.2010.10.00921074311Search in Google Scholar

27. Wittrant Y. et al.: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim. Biophys. Acta, 1704, 49-57, 2004.10.1016/j.bbcan.2004.05.00215363860Search in Google Scholar

28. Yuan H. et al.: Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis. J. Clin. Periodontol., 38, 11, 1029, 2011.10.1111/j.1600-051X.2011.01780.x22092474Search in Google Scholar

eISSN:
2300-6676
ISSN:
2084-980X
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, other, Pharmacology, Toxicology, Pharmacy